Core Insights - The company has advanced its 'Three-S' strategic plan (Stabilize, Streamline, and Strengthen) through the sale of its Dermacosmetics business, scaling its global operating growth model, and enhancing brand building capabilities, which are yielding positive results [1][6][8] - The company reaffirms its full-year 2025 adjusted EPS target range of $2.90 to $3.10 despite challenging market consumption trends [1][39] Financial Performance - Second Quarter 2025 net sales were $1.06 billion, a decrease of 0.9% year-over-year, impacted by divestitures and exited products [7][13] - Reported operating income was $45 million, compared to a loss of $27 million in the prior year, while adjusted operating income decreased by 2.9% to $135 million [7][17] - Diluted EPS improved to $0.00 from $(0.77) in the prior year, with adjusted EPS at $0.57, reflecting a 7.5% increase [19][12] Segment Performance - Consumer Self-Care Americas (CSCA) net sales were $622 million, down 1.9%, with growth in Nutrition and Upper Respiratory categories offset by declines in Digestive Health and Oral Care [21][22] - Consumer Self-Care International (CSCI) net sales increased by 0.7% to $434 million, driven by Pain & Sleep Aids and Upper Respiratory categories, despite a negative impact from divestitures [27][28] Strategic Initiatives - Project Energize, launched in Q1 2024, aims to enhance organizational agility and is expected to deliver annualized pre-tax savings of $140 million to $170 million by the end of 2026 [9][10] - The company anticipates that the sale of the Dermacosmetics business will strengthen its balance sheet and accelerate net leverage goals [8][39] Cash Flow and Balance Sheet - Year-to-date operating cash flow was $11 million, with cash inflow of $76 million in Q2 2025, and cash and cash equivalents on the balance sheet were $454 million as of June 28, 2025 [33][34] - Total debt on the balance sheet was $3.65 billion [34] Market Outlook - The company expects reported and organic net sales growth to be towards the lower end of their respective ranges for 2025, primarily due to infant formula industry dynamics and challenging market consumption trends [39][44] - The company believes its unique business model and extensive product offerings position it well to adapt to changing consumer behaviors and market conditions [37][39]

Core Viewpoint - Perrigo (PRGO) shows potential for significant upside, with a mean price target of $36.67 indicating a 36% increase from the current trading price of $26.96 [1] Price Targets - The average price target consists of three estimates ranging from a low of $30.00 to a high of $42.00, with a standard deviation of $6.11, suggesting variability in analyst predictions [2] - The lowest estimate indicates an 11.3% increase, while the highest suggests a 55.8% upside [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are increasingly optimistic about PRGO's earnings prospects, as evidenced by upward revisions in EPS estimates [11] - The Zacks Consensus Estimate for the current year has risen by 0.3% over the past month, with one estimate increasing and no negative revisions [12] - PRGO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][7] - Analysts often set optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism and not be the sole basis for investment decisions [10]

Core Viewpoint - Perrigo Company plc (PRGO) is set to report its second-quarter 2025 earnings on August 6, with expectations of sales at $1.08 billion and earnings per share (EPS) at 59 cents, following a previous earnings surprise of 7.14% [1][7]. Group 1: Upcoming Earnings Expectations - The Zacks Consensus Estimate for sales in the Consumer Self Care Americas (CSCA) segment is $636 million, while the model estimate is $641 million. For the Consumer Self Care International (CSCI) segment, the estimates are $445 million and $439 million, respectively [3]. - Sales in the second quarter are anticipated to be affected by exited businesses, product line reductions, and unfavorable currency movements [2][7]. Group 2: Strategic Developments - Investors are looking for updates on the deal with KKR-backed Kairos Bidco AB regarding the sale of Perrigo's Dermacosmetics-branded business for up to €327 million, as well as insights on the expected impact of macroeconomic pressures in future quarters [4][7]. Group 3: Earnings Performance History - Perrigo has shown a decent earnings performance over the last four quarters, beating estimates in three of those quarters and missing once, resulting in an average surprise of 4.36% [5].

Company Overview - Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions primarily in North America and Europe [2] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering trusted self-care solutions that do not require a prescription, ensuring accessibility and choice for consumers [2] Business Model - Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [3] Upcoming Events - The President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on August 12th at 9:00 AM EDT [1]

Core Viewpoint - Perrigo Company plc is set to release its second quarter 2025 financial results on August 6, 2025, and will host a conference call to discuss these results [1] Company Overview - Perrigo Company plc is a leading provider of Consumer Self-Care Products with over a century of experience in delivering high-quality health and wellness solutions primarily in North America and Europe [3] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering accessible self-care solutions that do not require a prescription [3] Business Model - Perrigo's business model is characterized by its complementary businesses, where cash-generative store brand private label offerings support investments in leading brands such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula® [4]

Core Viewpoint - Perrigo (PRGO) shares have increased by 2.9% over the past four weeks, closing at $27.09, with a mean price target of $36.67 indicating a potential upside of 35.4% [1] Price Targets - The average price target consists of three short-term estimates ranging from a low of $30.00 to a high of $42.00, with a standard deviation of $6.11, suggesting a potential increase of 10.7% to 55% from the current price [2] - A low standard deviation indicates a strong agreement among analysts regarding the price targets, which can be a useful metric for investors [2][9] Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher for PRGO, which is a positive indicator for potential stock upside [4][11] - The Zacks Consensus Estimate for the current year has increased by 0.3% over the past month, with no negative revisions, reflecting growing optimism [12] Zacks Rank - PRGO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the exact price movement, it does provide a directional guide for potential stock performance [14]

Company Overview - Perrigo Company plc, based in Dublin, Ireland, was formed from the merger of Perrigo Company and Elan Corporation in December 2013, focusing on over-the-counter (OTC) markets and wellness solutions [12] - The company has a diversified revenue stream and operates in segments designed to enhance individual well-being [12] Investment Ratings - Perrigo is currently rated as a 2 (Buy) on the Zacks Rank, with a VGM Score of B, indicating a favorable investment outlook [12] - The company has a Momentum Style Score of B, with shares increasing by 2.9% over the past four weeks [13] Earnings Estimates - Two analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.04 to $3.04 per share [13] - Perrigo has an average earnings surprise of +4.4%, suggesting a positive trend in earnings performance [13] Investment Considerations - With a solid Zacks Rank and strong Momentum and VGM Style Scores, Perrigo is recommended for investors looking for potential growth opportunities [13]

Core Insights - Perrigo Company plc has signed an agreement to sell its Dermacosmetics branded business to Kairos Bidco AB for up to €327 million, which includes €300 million in upfront cash and up to €27 million in potential future milestone payments [1][2] - This transaction is part of Perrigo's 'Three-S' plan aimed at stabilizing, streamlining, and strengthening the organization by focusing on high-growth opportunities [1][2] - The Dermacosmetics business generated approximately €125 million in net sales in 2024, contributing about 5% to Perrigo's adjusted operating income for that year [3] Financial Details - The expected net proceeds from the transaction will be directed towards previously announced capital allocation priorities, including strengthening the company's balance sheet [2] - The transaction is anticipated to close in the first quarter of 2026, pending customary closing conditions and regulatory approvals [3] Strategic Focus - The sale allows Perrigo to sharpen its focus on core self-care categories that align with its One Perrigo model, enhancing its ability to drive sustainable growth and deliver greater value [2] - KKR, the acquiring firm, aims to leverage its global network and operational expertise to accelerate growth in the Dermacosmetics business [2][9]

Core Viewpoint - Perrigo Company plc is optimizing its growth model focused on global Category Leadership and Market Activation to enhance agility, innovation, and sustainable growth, aligning with its 'Three-S' plan [1][2]. Organizational Changes - Roberto Khoury has been appointed as EVP and Chief Commercial Officer to lead global market activation, while the roles of EVP and President CSCI and EVP and President CSCA will be discontinued, with Triona Schmelter leaving the organization [1][4][6]. Growth Model Highlights - The new alignment aims to enhance speed, agility, and scalability, reducing bureaucracy and allowing Perrigo to serve a broader consumer base across various price points [6]. - The growth model has already shown success in the CSCI business and is increasingly effective in the CSCA business, achieving accelerated regulatory milestones and market share gains [6]. Portfolio Optimization - The alignment is designed to unlock value from both brand and store brand portfolios, creating new growth opportunities through enhanced global brand-building capabilities [6]. - Market-empowered activation and strong customer relationships will drive execution excellence in the new model [6]. Leadership Alignment - Roberto Khoury will oversee operating results in both CSCI and CSCA, collaborating closely with David Ball, who is responsible for global category leadership [6]. Financial Guidance - The organizational changes will not affect the full-year 2025 adjusted EPS guidance or reporting segments [6].

Group 1 - Good Start® | Dr. Brown's™ is launching a month-long giveaway contest starting July 1, 2025, to support families in need by awarding 100 winners with two months' worth of Gentle Pro™ baby formula and Dr. Brown's products, valued at $516.49 each [1][4] - The contest will also include a donation of over 4,000 cans of Gentle Pro™ formula to Baby2Baby, supporting over 95,000 feedings, with a total donation value exceeding $85,000 [2][3] - The campaign aims to help parents navigate their baby's formula-feeding journey while increasing the impact of donations to children in need [3] Group 2 - The contest is open to legal U.S. residents aged 18 and older, with no purchase necessary, and winners will be announced by August 6, 2025 [4] - Good Start® | Dr. Brown's™ infant formula solutions focus on providing high-quality, trusted baby formulas designed for babies with sensitive tummies, utilizing gut-friendly probiotics and advanced hydrolysis processes [5] - Dr. Brown's Company is recognized for its innovative feeding products, having won multiple awards for its baby bottles and feeding solutions [6] Group 3 - Perrigo Company plc, the parent company of Good Start® | Dr. Brown's™, is a leading provider of Consumer Self-Care Products and OTC health solutions aimed at enhancing individual well-being [7]